Natural Killer Cell
Immune System Signaling Pathways
UH Seidman Cancer Center names division chief, immunotherapy center director
Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.
FDA grants orphan drug designation to natural killer cell therapy for GI cancers
The FDA granted orphan drug designation to CYNK-101, an investigational natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
FDA grants fast track designation to natural killer cell therapy for GI cancers
The FDA granted fast track designation to CYNK-101, a natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
FDA clears IND application for CAR natural killer cell therapy to treat solid tumors
The FDA cleared an investigational new drug application for FT536, a chimeric antigen receptor natural killer cell therapy designed to treat adults with certain relapsed or refractory solid tumors.
FDA grants fast track designation to natural killer cell therapy for advanced AML
The FDA granted fast track designation to CYNK-001 for the treatment of adults with relapsed or refractory acute myeloid leukemia.
FDA grants orphan drug designation to NKX101 for acute myeloid leukemia
The FDA granted orphan drug designation to NKX101 for treatment of acute myeloid leukemia.
VIDEO: Natural killer cell therapies for B-cell lymphoma perform "surprisingly well"
In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.
FDA grants RMAT designation to natural killer cell therapy for advanced lymphoma
The FDA granted regenerative medicine advanced therapy designation to FT516, a natural killer cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
FDA clears application for natural killer cell therapy to treat gastrointestinal cancers
The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.